Renal histopathological and biochemical changes following adjuvant intervention of Momordica charantia and antiretroviral therapy in diabetic rats | ||
| Iranian Journal of Basic Medical Sciences | ||
| مقاله 17، دوره 22، شماره 11، بهمن 2019، صفحه 1359-1367 اصل مقاله (951.96 K) | ||
| نوع مقاله: Short Communication | ||
| شناسه دیجیتال (DOI): 10.22038/ijbms.2019.31848.7663 | ||
| نویسندگان | ||
| Ugochukwu Offor* 1، 2؛ Edwin Coleridge Stephen Naidu1؛ Oluwatosin Olalekan Ogedengbe1، 3؛ Ayoola Isaac Jegede1، 4؛ Aniekan Imo Peter1، 5؛ Okpara Azu Onyemaechi1، 6 | ||
| 1Department of Clinical Anatomy, School of Laboratory Medicine and Medical Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, South Africa | ||
| 2Department of Preclinical Sciences, School of Health Care Sciences, Faculty of Health Sciences, University of Limpopo, South Africa | ||
| 3Department of Anatomy, College of Medicine and Health Sciences, Afe Babalola University, Ado Ekiti, Nigeria | ||
| 4Department of Basic Sciences, School of Medicine, Copperbelt University, Zambia | ||
| 5Department of Anatomy, Faculty of Basic Medical Sciences, University of Uyo-Nigeria, Nigeria | ||
| 6Department of Anatomy, School of Medicine, University of Namibia, Windhoek, Namibia | ||
| چکیده | ||
| Objective(s): Diabetic nephropathy (DN) is an important primary cause of end-stage kidney disease. This study explores the mechanisms of the reno-protective effects of Momordica charantia (M. charantia) in diabetic rats following treatment with highly active antiretroviral therapy (HAART) regimen triplavar. Materials and Methods: Adult male Sprague-Dawley rats (n=48) were divided into 7 groups (A-G).Treatment groups (B-G) had 7 animals per group and control group (Group A) had 6 animals per group. Diabetes was induced with streptozotocin (STZ) by intraperitoneal injection (STZ 45 mg/kg body weight). The animals were euthanized on the tenth week with kidneys removed for examination and blood obtained via cardiac puncture. Results: Key renal parameters showed no albuminuria, normal blood urea nitrogen (BUN), serum creatinine and electrolytes in all groups treated with M. charantia. Untreated diabetic (Group B) and HAART treated diabetic (Group C) showed severe albuminuria, a significantly raised BUN and serum creatinine (P<0.05) and gross electrolyte disturbances. Blood glucose levels were consistently and significantly raised in all groups not receiving the adjuvant M. charantia (P<0.05). Levels of oxidative stress enzymes Superoxide dismutase (SOD), Catalase and activities of Reduced Gluthaione (GSH) and Malondiadehyde (MDA) were significantly lower in all groups not receiving M. charantia. Histopathology in untreated diabetic and HAART treated animals showed severe degenerative changes in the glomeruli and inflammatory cellular infiltration while M. charantia treated animals showed an essentially normal glomerular appearance with capillary loops and normal cytoarchitecture. Conclusion: M. charantia extract administration improved blood glucose levels, reinstates renal function, reduces body weight loss and restores hyperglycemia. | ||
| کلیدواژهها | ||
| Antiretroviral therapy؛ Diabetic nephropathy؛ Histopathology؛ Kidney؛ Momordica charantia؛ Sprague-Dawley rats | ||
| مراجع | ||
|
1. Ji X, Li C, Ou Y, Li N, Yuan K, Yang G, et al. Andrographolide ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated renal oxidative stress and inflammation via Akt/NF-κB pathway. Mol Cell Endocrinol 2016; 437:268-279. 2. Zheng S, Powell DW, Zheng F, Kantharidis P, Gnudi L. Diabetic nephropathy: proteinuria, inflammation, and fibrosis. J Diabetes Res 2016; 2016: 5241549-5241551. 3. Toth-Manikowski S, Atta MG. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res 2015; 2015:697010-697026. 4. Elias A, Nelson B, Oputiri D, Geoffrey O-BP. Antiretroviral toxicity and oxidative stress. Am J Pharmacol Toxicol 2013; 8:187-197. 5. Ding H, Triggle CR. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc Health Risk Manag 2005; 1:55-71. 6. Offor U, Jegede AI, Onanuga IO, Naidu EC, Azu OO. Does hypoxis hemerocallidea mitigate renal histopathological injuries following highly active antiretroviral therapy? An experimental animal study. Minerva Urol Nefrol 2017; 69:391-399. 7. Kwatra D, Dandawate P, Padhye S, Anant S. Bitter melon as a therapy for diabetes, inflammation, and cancer: a panacea?. Curr Pharmacol Rep 2016; 2:34-44. 8. Abas R, Othman F, Thent ZC. Effect of Momordica charantia fruit extract on vascular complication in type 1 diabetic rats. EXCLI J 2015; 14:179-189. 9. Kang J, Zeng B, Tang S, Wang M, Han X, Zhou C, et al. Effects of Momordica charantia Saponins on In vitro ruminal fermentation and microbial population. Asian-Australas J Anim Sci 2016; 29:500-508. 10. Perumal V, Khoo W, Abdul Hamid A, Ismail A, Shaari K, Murugesu S, et al. Evaluation of antidiabetic properties of Momordica charantia in streptozotocin induced diabetic rats using metabolomics approach. Int Food Res J 2015; 22:1298-1306. 11. Aljohi A, Matou-Nasri S, Al-Khafaji N, Slevin M, Ahmed N. Momordica charantia (bitter melon) extracts promote angiogenesis in vitro via the receptor for advanced glycation endproducts (RAGE). Food Funct 2016; 9:5728-5739. 12. Etuk E. Animal models for studying diabetes mellitus. Agric Biol JN Am 2010; 1:130-134. 13. Hodges DM, DeLong JM, Forney CF, Prange RK. Improving the thiobarbituric acid-reactive-substances assay for estimating lipid peroxidation in plant tissues containing anthocyanin and other interfering compounds. Planta 1999; 207:604-611. 14. Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 2006; 1:3159-3165. 15. Weydert CJ, Cullen JJ. Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat Protoc 2010; 5:51-66. 16. Moyo D, Tanthuma G, Mushisha O, Kwadiba G, Chikuse F, Cary MS, et al. Diabetes mellitus in HIV-infected patients receiving antiretroviral therapy. S Afr Med J 2013; 104:40-42. 17. Röling J, Schmid H, Fischereder M, Draenert R, Goebel F. HIV-associated renal diseases and highly active antiretroviral therapy—induced nephropathy. Clin Infect Dis 2006; 42:1488-1495. 18. Muhammed M, JavedI K. Collapsing focal segmental glomerulosclerosis: a morphological lesion in search of Nosologic identity. Nephro-Urology Monthly 2011; 2011:240-246. 19. Teoh SL, Latiff AA, Das S. Histological changes in the kidneys of experimental diabetic rats fed with Momordica charantia (bitter gourd) extract. Rom J Morphol Embryol 2010; 51:91-95. 20. Alsahli M, Gerich JE. Hypoglycemia in patients with diabetes and renal disease. J Clin Med 2015; 4:948-964. 21. Nerurkar PV, Johns LM, Buesa LM, Kipyakwai G, Volper E, Sato R, et al. Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. J Neuroinflammation 2011; 8:64-83. 22. Raish M, Ahmad A, Jan BL, Alkharfy KM, Ansari MA, Mohsin K, et al. Momordica charantia polysaccharides mitigate the progression of STZ induced diabetic nephropathy in rats. Int J Biol Macromol 2016; 91:394-399. 23. Raza H, Ahmed I, John A, Sharma AK. Modulation of xenobiotic metabolism and oxidative stress in chronic streptozotocin‐induced diabetic rats fed with Momordica charantia fruit extract. J Biochem Mol Toxicol 2000; 14:131-139. 24. Guo L, Chen Z, Amarnath V, Davies SS. Identification of novel bioactive aldehyde-modified phosphatidylethanolamines formed by lipid peroxidation. Free Radical Biol Med 2012; 53:1226-1238. 25. Daniel P, Supe U, Roymon M. A review on phytochemical analysis of Momordica charantia. Int J Adv Pharm Biol Chem 2014; 3:214-220. 26. Upadhyay A, Agrahari P, Singh D. A review on salient pharmacological features of Momordica charantia. Int J Pharmacol 2015; 11:405-413. 27. Kumar GS, Shetty A, Salimath P. Modulatory effect of bitter gourd (Momordica charantia LINN.) on alterations in kidney heparan sulfate in streptozotocin-induced diabetic rats. J Ethnopharmacol 2008; 115:276-283. 28. Sharma N, Panda S, Kar A. Momordica charantia fruit extract and glibenclamide synergistically ameliorate corticosteroid induced diabetes mellitus in mice. Int J Pharm Bio Sci 2014; 5:23-32. 29. Efird JT, Choi YM, Davies SW, Mehra S, Anderson EJ, Katunga LA. Potential for improved glycemic control with dietary Momordica charantia in patients with insulin resistance and pre-diabetes. Int J Environ Res Public Health 2014; 11:2328-2345. 30. Abdollahi M, Zuki A, Rezaeizadeh A, Goh Y, Noordin M. Effects of Momordica charantia aqueous extract on renal histopathological changes associated with streptozotocin-induced diabetes mellitus type II in neonatal rats. J Med Plants Res 2011; 5:1779-1787. 31. Parmar K, Patel S, Patel B, Patel MB. Effects of bittergourd (Momordica charantia) fruit juice on glucose tolerance and lipid profile in type-l l diabetic rats. Int J Drug Dev Res 2011; 3:139-146. | ||
|
آمار تعداد مشاهده مقاله: 698 تعداد دریافت فایل اصل مقاله: 410 |
||